Drug Trial Radar · NCT06361199
Proximod Pharmacokinetics in Healthy Subjects and Patients With Rheumatoid Arthritis
Last checked: Nov 19, 2026Latest source record: Apr 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
22
Actual
Start
Dec 16, 2021
Primary completion
Feb 16, 2022
Study completion Oct 8, 2023
Sponsor
- Lead sponsor
- Longevity Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 11, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate the tolerability, pharmacokinetics and pharmacodynamics of Proximod in healthy subjects and patients with rheumatoid arthritis. The main questions it arms to answer are: 1. to evaluate the safety and tolerance of Proximod in health subjects after repeated doses. 2. to assess the pharmacokinetics and pharmacodynamics of Proximod in healthy subjects after repeated doses. 3. to evaluate the safety and tolerance of Proximod in patients with rheumatoid arthritis. 4. to evaluate the pharmacokinetics and pharmacodynamics of Proximod in patients with rheumatoid arthritis. Participants will receive test tablets or placebo at the indicated date and collect blood samples.
Conditions
- Rheumatoid Arthritis
Interventions
ProximodDrug
Multiple-dose to establish the safety and PK profile in both healthy subjects and patients with rheumatoid arthritis
PlaceboDrug
Placebo controlled
Primary outcomes
What the sponsor says the trial is designed to measure.
- Peak plasma concentration (Cmax)Time frame: Up to 48 days
- Time to peak plasma concentration (Tmax)Time frame: Up to 48 days
- The lowest plasma concentration (Cmin)Time frame: Up to 48 days
- Half-life (t1/2)Time frame: Up to 48 days
- Area under the plasma concentration versus time curve (AUC)Time frame: Up to 48 days
- Number of adverse events and number of participants with adverse eventsTime frame: Up to 48 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The first hospital of Jilin University
Changchun, Jilin, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.